StockData

Puma Biotechnology vs UroGen Pharma

PBYI and URGN side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How PBYI and URGN compare

UroGen Pharma is the larger company, worth 4.0 times as much as Puma Biotechnology ($1.5B against $369M).

UroGen Pharma grew revenue faster over the last twelve months (100% versus −2.9% for Puma Biotechnology).

Puma Biotechnology keeps more of each dollar of sales as profit, with a net margin of 11.6% compared with −51.7% at UroGen Pharma.

Puma Biotechnology scores higher on the StockData Score (14 against 6 for UroGen Pharma), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricPBYIURGN
Size and price
Market cap$369M$1.5B
Share price$7.14$29.87
Change, 1 year46.0%25.7%
Change, 5 years121%146%
Beta (5Y)1.322.73
Employees179291
StockData Score
Total score14 (better)6
Valuation score2 (better)0
Growth score23 (better)
Performance score5 (better)2
Health score5 (better)1
Dividend score00
Valuation
P/E13.7×–
P/S1.6× (better)7.7×
P/B2.7×–
EV/EBITDA6.9×–
P/FCF9.0×–
FCF yield11.2% (better)−10.9%
Fair value$8.84–
Margin of safety19.2%–
Growth
Revenue growth (TTM)−2.9%100% (better)
Revenue growth, 5Y average0.29%56.2% (better)
Net income growth (TTM)−44.9%–
EPS growth (TTM)−46.9%–
Profitability
Gross margin74.8%90.8% (better)
Operating margin13.2% (better)−35.3%
Net margin11.6% (better)−51.7%
FCF margin17.8% (better)−84.3%
Return on equity22.0%–
Return on invested capital42.7%–
Financial health
Debt / equity0.00–
Net debt / EBITDA−2.12–
Interest coverage8.6×–
Current ratio2.913.80 (better)
Altman Z-score−2.90−2.55 (better)
Piotroski F-score8 (better)0
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions74.9%86.8%
Held by insiders18.9%5.6%
Insider net buying, 12 months−$2.1M (better)−$4.5M
Short interest, % of float10.3%11.1%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.